EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 29 / No 12 (Décembre 2013) Med Sci (Paris), 29 12 (2013) 1161-1166 References
Free Access
Issue
Med Sci (Paris)
Volume 29, Number 12, Décembre 2013
Page(s) 1161 - 1166
Section Forum
DOI https://doi.org/10.1051/medsci/20132912021
Published online 20 December 2013
  1. Avis du Comité technique des vaccinations et du Conseil supérieur d’hygiène publique de France relatif à la vaccination contre les papillomavirus humains 6, 11, 16 et 18. Paris, 9 mars, 2007. Disponible sur http://www.cngof.asso.fr/D_TELE/vaccin_hpv_0307.pdf. [Google Scholar]
  2. Avis du Haut conseil de la santé publique relatif à la vaccination contre les infections à papillomavirus humains des jeunes filles de 14 à 23 ans. 17 décembre 2010. Disponible sur http://www.hcsp.fr/docspdf/avisrapports/hcspa20101217_ppmvjf1423.pdf. [Google Scholar]
  3. Fagot JP, Boutrelle A, Ricordeau P, et al. HPV vaccination in France: uptake, costs and issues for the National Health. Insurance Vaccine 2011 ; 29 : 3610–3616. [Google Scholar]
  4. Avis du Haut conseil de la santé publique relatif à la révision de l’âge de la vaccination contre les infections à papillomavirus humains des jeunes filles. Paris, 28 septembre 2012. Disponible sur http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20120928_agevaccpapilljeunesfilles.pdf. [Google Scholar]
  5. Le calendrier des vaccinations et les recommandations vaccinales 2013 selon l’avis du Haut Conseil de la Santé publique. Bull Epidemiol Hebd 2013 ; 14–15 : 131–158. [Google Scholar]
  6. Rapport du Conseil supérieur d’hygiène publique de France relative à la vaccination contre les papillomavirus. Paris, 23 mars 2007. Disponible sur http://www.sante.gouv.fr/dossiers/cshpf/r_mt_230307_papillomavirus.pdf. [Google Scholar]
  7. La santé des collégiens en France, 2010. Paris, INPES, 2012. Disponible sur http://www.inpes.sante.fr/CFESBases/catalogue/pdf/1412.pdf. [Google Scholar]
  8. Marlow LA, Waller J, Wardle J. Parental attitudes to pre-pubertal HPV vaccination. Vaccine 2007 ; 25 : 1945–1952. [CrossRef] [PubMed] [Google Scholar]
  9. Waller J, Marlow LA, Wardle J. Mothers’s attitude towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol Biomarkers Prev 2006 ; 15 : 1257–1261. [CrossRef] [PubMed] [Google Scholar]
  10. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 2007 ; 40 : 108–115. [CrossRef] [PubMed] [Google Scholar]
  11. Dempsey AF, Zimet GD, Davis RL, et al. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 2006 ; 117 : 1486–1493. [CrossRef] [PubMed] [Google Scholar]
  12. Pelissier G, Bastides F. Vaccination HPV et prévention du cancer cervical en pratique de médecine générale. Enquête conduite auprès des médecins généralistes du départment de l’Eure et Loire et du Cher. Rev Prat 2008 ; 58 : 25–31. [Google Scholar]
  13. Piana L, Noel G, Uters M, et al. Opinions et pratiques des médecins généralistes face à la vaccination anti-papillomavirus. Med Mal Infect 2009 ; 39 : 789–797. [CrossRef] [PubMed] [Google Scholar]
  14. Lutringer-Magnin D, Kalecinski J, Barone G, et al. Human papillomavirus (HPV) vaccination: perception and practice among french general practitioners in the year since licensing. Vaccine 2011 ; 29 : 5322–5328. [CrossRef] [PubMed] [Google Scholar]
  15. Donovan B, Guy R, Grulich AE, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of a national sentinel surveillance data. Lancet Infect Dis 2011 ; 11 : 39–44. [CrossRef] [PubMed] [Google Scholar]
  16. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011 ; 87 : 544–547. [CrossRef] [PubMed] [Google Scholar]
  17. Kahn JA, Bernstein DI. HPV vaccination. Too soon for 2 doses? JAMA 2013 ; 309 : 1832–1834. [CrossRef] [PubMed] [Google Scholar]
  18. Romanowski B, Schwartz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Results from a randomized study. Human Vaccine 2011 ; 7 : 1374–1386. [CrossRef] [Google Scholar]
  19. Kreimer AR, Rodriguez AC, Hilddesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011 ; 103 : 1444–1451. [CrossRef] [PubMed] [Google Scholar]
  20. Dobson SRM, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents versus 3 doses in young women: a randomized clinical trial. JAMA 2013 ; 309 : 1793–1802. [CrossRef] [PubMed] [Google Scholar]
  21. Smolen KK, Gelinas L, Franzen L, et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012 ; 30 : 3572–3579. [CrossRef] [PubMed] [Google Scholar]
  22. LaMontagne DS, Thiem VD, Huong VM, et al. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedule: results 29 to 32 months after third dose. J Infect Dis 2013 ; doi:10.1093/infdis/jit363. [Google Scholar]
  23. Vaccination contre les HPV: passage du schéma à trois doses au schéma à deux doses chez les adolescentes âgées de moins de 15 ans. Bulletin de l’Office fédéral de la santé publique suisse 2012 ; 6 : 106–110. Disponible sur http://www.bag.admin.ch/dokumentation/publikationen/01435/11505/12789/index.html?lang=fr&sort. [Google Scholar]
  24. British Columbia HPV vaccine immunization schedule: human papillomavirus (HPV) vaccine extended schedule for girls between the ages of 9–13 years. Disponible sur : http://immunizebc.ca/sites/default/files/docs/HPVprofessionalQA_Jan2011_final.pdf. [Google Scholar]
  25. Quebec HPV immunization schedule. Disponible sur http://www.msss.gouv.qc.ca/sujets/santepub/vaccination/index.php?aid=136. [Google Scholar]
  26. Lefevere E, Hens N, Theeten H, et al. Like mother, like daughter? Mother’s history of cervical cancer screening and daughter’s human papillomavirus vaccine uptake in Flanders (Belgium). Vaccine 2011 ; 29 : 8390–8396. [CrossRef] [PubMed] [Google Scholar]
  27. Chao C, Slezak JM, Coleman KJ, et al. Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls. Am J Public Health 2009 ; 99 : 1137–1142. [CrossRef] [PubMed] [Google Scholar]
  28. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts : an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health 2012 ; 102 : 833–835. [CrossRef] [PubMed] [Google Scholar]
  29. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland sexual health services. NZ Med J 2011 ; 124 : 51–58. [Google Scholar]
  30. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011 ; 377 : 2085–2092. [CrossRef] [PubMed] [Google Scholar]
  31. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012 ; 206 : 1645–1651. [CrossRef] [PubMed] [Google Scholar]
  32. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States. National health and nutrition examination surveys, 2003–2010. J Infect Dis 2013 ; 208 : 385–393. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.